Today announced preliminary outcomes from a phase 2 clinical study of ALKS 33.

Alkermes announces preliminary results from ALKS 33 Stage 2 study in alcoholic beverages dependence Alkermes, Inc. today announced preliminary outcomes from a phase 2 clinical study of ALKS 33, one of Alkermes’ proprietary applicants for the treating reward disorders and other central nervous program disorders. The 12-week study was made to assess the protection and efficacy of daily oral administration of three different dosage levels of ALKS 33 in comparison to placebo in 400 alcohol dependent patients http://sildenafilfr.com/le-viagra-pour-femme.html .

2. In addition, it reduces the rate of heartbeat and improves the blood circulation. 3. Improves the energy of concentration. 4. Meditation helps in improving the storage also. 5. It not merely reduces the stress and anxiety levels, but also assists in gaining self-confidence. 6. By practicing meditation regularly, it helps in achieving higher state of mind giving a sense of clarity in our vision. 7. Self-control and better co-ordination of mind body and soul can be achieved. 8. Any type of mental disorders or any other issues which affect mind could be sorted out by meditating.